Skip to main content
Fig. 1 | Journal of Translational Medicine

Fig. 1

From: Tumor angiogenesis at baseline identified by 18F-Alfatide II PET/CT may predict survival among patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy

Fig. 1

Two representatives 18F-Alfatide II PET/CT scans of responding tumors (a SUVmax = 5.18) and non-responding tumors (b SUVmax = 9.80). (Top panel) Scans from a patient with 18F-Alfatide uptake at baseline and 4 weeks after CCRT who showed a partial response to CCRT, and (bottom panel) scans from another patient with stable disease

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us